IRAK4-IN-1
10mM in DMSO
- Product Code: 199027
CAS:
1820787-94-7
| Molecular Weight: | 337.42 g./mol | Molecular Formula: | C₁₉H₂₃N₅O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
IRAK4-IN-1 is a potent and selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), a key component in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. It is primarily used in research to modulate innate immune responses and inflammation. Due to its ability to block IRAK4 kinase activity, it serves as a valuable tool in studying inflammatory diseases, autoimmune disorders, and certain cancers where TLR/IL-1R pathways are overactive.
In oncology research, IRAK4-IN-1 has shown utility in models of hematological malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia, where aberrant signaling through MyD88 and IRAK4 drives tumor survival. By inhibiting IRAK4, this compound can suppress downstream NF-κB activation and reduce pro-inflammatory cytokine production, including TNF-α, IL-6, and IL-1β.
Its application extends to autoimmune disease models like rheumatoid arthritis and lupus, where dampening innate immune signaling can reduce disease progression. Researchers also use IRAK4-IN-1 to validate IRAK4 as a therapeutic target and to explore combination therapies with other kinase inhibitors or immunomodulatory agents.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,200.00 |
+
-
|
IRAK4-IN-1
IRAK4-IN-1 is a potent and selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), a key component in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. It is primarily used in research to modulate innate immune responses and inflammation. Due to its ability to block IRAK4 kinase activity, it serves as a valuable tool in studying inflammatory diseases, autoimmune disorders, and certain cancers where TLR/IL-1R pathways are overactive.
In oncology research, IRAK4-IN-1 has shown utility in models of hematological malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia, where aberrant signaling through MyD88 and IRAK4 drives tumor survival. By inhibiting IRAK4, this compound can suppress downstream NF-κB activation and reduce pro-inflammatory cytokine production, including TNF-α, IL-6, and IL-1β.
Its application extends to autoimmune disease models like rheumatoid arthritis and lupus, where dampening innate immune signaling can reduce disease progression. Researchers also use IRAK4-IN-1 to validate IRAK4 as a therapeutic target and to explore combination therapies with other kinase inhibitors or immunomodulatory agents.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :